Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Operating activities:
Net (loss) income	$ (20,479)	$ 33,446
Adjustments to reconcile net (loss) income to net cash flows from operating activities
Depreciation and amortization	456	226
Impairment loss on equipment	78
Accretion of debt discount and loan costs	1,782	1,491
Amortization of intangible assets	2,578	2,735
Provision for inventory obsolescence	412	21
Stock-based compensation expense	4,004	6,000
Deferred income taxes		(15,972)
Bargain purchase gain		(27,336)
Changes in assets and liabilities, net of effect of acquisition:
Accounts receivable	(423)	(2,458)
Inventories	(489)	2,639
Prepaid expenses and other assets	1,454	1,034
Accounts payable and accrued liabilities	(1,118)	3,179
Deferred revenue		(21,716)
Net cash flows used in operating activities	(11,745)	(16,711)
Investing activities:
BELBUCA® acquisition	(1,951)
Purchase of equipment	(122)	(2)
Net cash flows used in investing activities	(2,073)	(2)
Financing activities:
Proceeds from issuance of Series B preferred stock	50,000
Equity finance costs	(1,509)
Proceeds from notes payable		45,000
Proceeds from exercise of stock options	306
Payment on note payable		(30,000)
Payment of deferred financing fees	(450)	(2,798)
Net cash flows provided by financing activities	48,347	12,202
Net change in cash and cash equivalents	34,529	(4,511)
Cash and cash equivalents at beginning of period	21,195	32,019
Cash and cash equivalents at end of period	55,724	27,508
Cash paid for interest	$ 3,249	2,373
Non-cash Operating, Financing and Investing Activities:
Common stock issuance upon retirement, shares	2,119,925
Common stock issuance upon retirement	$ 5,300
Fair value of bargain purchase price of BELBUCA acquisition		$ 27,300
Series B Non-Voting Convertible Preferred Stock [Member]
Non-cash Operating, Financing and Investing Activities:
Accrued financing expenses	$ 600